Journal
EUROPEAN HEART JOURNAL
Volume 42, Issue 48, Pages 4891-+Publisher
OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehab497
Keywords
Canagliflozin; SGLT2 inhibitors; Hyperkalaemia; Potassium; Type 2 diabetes mellitus; Chronic kidney disease
Categories
Funding
- Janssen Research & Development, LLC
- academic-ed Steering Committee
- Academic Research Organization, George Clinical
Ask authors/readers for more resources
The study findings suggest that SGLT2 inhibition with canagliflozin may reduce the risk of hyperkalaemia in patients with type 2 diabetes mellitus and chronic kidney disease treated with renin-angiotensin-aldosterone system inhibitors without increasing the risk of hypokalaemia.
Aims Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits the optimal use of agents that block the renin-angiotensin-aldosterone system, particularly in patients with chronic kidney disease (CKD). In patients with CKD, sodiumglucose cotransporter 2 (SGLT2) inhibitors provide cardiorenal protection, but whether they affect the risk of hyperkalaemia remains uncertain. Methods and results The CREDENCE trial randomized 4401 participants with T2DM and CKD to the SGLT2 inhibitor canagliflozin or matching placebo. In this post hoc analysis using an intention-to-treat approach, we assessed the effect of canagliflozin on a composite outcome of time to either investigator-reported hyperkalaemia or the initiation of potassium binders. We also analysed effects on central laboratory-determined hyper- and hypokalaemia (serum potassium >= 6.0 and <3.5 mmol/L, respectively) and change in serum potassium. At baseline, the mean serum potassium in canagliflozin and placebo arms was 4.5 mmol/L; 4395 (99.9%) participants were receiving renin-angiotensin system blockade. The incidence of investigator-reported hyperkalaemia or initiation of potassium binders was lower with canagliflozin than with placebo [occurring in 32.7 vs. 41.9 participants per 1000 patient-years; hazard ratio (HR) 0.78, 95% confidence interval (CI) 0.64-0.95, P=0.014]. Canagliflozin similarly reduced the incidence of laboratory-determined hyperkalaemia (HR 0.77, 95% CI 0.61-0.98, P=0.031), with no effect on the risk of hypokalaemia (HR 0.92, 95% CI 0.71-1.20, P=0.53). The mean serum potassium over time with canagliflozin was similar to that of placebo. Conclusion Among patients treated with renin-angiotensin-aldosterone system inhibitors, SGLT2 inhibition with canagliflozin may reduce the risk of hyperkalaemia in people with T2DM and CKD without increasing the risk of hypokalaemia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available